Maipu Medical released its 2026 half-year report. First-half operating revenue was 190 million yuan, up 20.3% year on year. Net profit attributable to the parent was 56.58 million yuan, up 19.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 53.94 million yuan, up 17.3% year on year. Second-quarter operating revenue was 111 million yuan, up 32.5% year on year, and net profit attributable to the parent was 35.87 million yuan, up 55.0% year on year. As of the end of the second quarter, the company's total assets were 901 million yuan, up 0.7% from the end of the previous year, and net assets attributable to the parent were 811 million yuan, up 1.7% from the end of the previous year. The company said its main operating businesses and main products had not undergone major changes, that it continued to make high-intensity research and development investments, focused on the neurosurgery field, and steadily advanced its overseas channel layout.
Medprin Regenerative Medical Technologies Co. Ltd.First-half net profit up 19.6% and Q2 profit up 55% year on year.
